- Home
- TAC vs CERT Comparison
TAC vs CERT Comparison
Compare TAC & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAC
- CERT
- Stock Information
- Founded
- TAC 1909
- CERT 2008
- Country
- TAC Canada
- CERT United States
- Employees
- TAC N/A
- CERT N/A
- Industry
- TAC Electric Utilities: Central
- CERT Retail: Computer Software & Peripheral Equipment
- Sector
- TAC Utilities
- CERT Technology
- Exchange
- TAC Nasdaq
- CERT Nasdaq
- Market Cap
- TAC 2.7B
- CERT 2.3B
- IPO Year
- TAC N/A
- CERT 2020
- Fundamental
- Price
- TAC $9.76
- CERT $11.36
- Analyst Decision
- TAC Buy
- CERT Buy
- Analyst Count
- TAC 2
- CERT 6
- Target Price
- TAC $19.75
- CERT $15.60
- AVG Volume (30 Days)
- TAC 1.3M
- CERT 1.7M
- Earning Date
- TAC 05-07-2025
- CERT 05-05-2025
- Dividend Yield
- TAC 1.79%
- CERT N/A
- EPS Growth
- TAC N/A
- CERT N/A
- EPS
- TAC 0.00
- CERT N/A
- Revenue
- TAC $1,847,844,992.00
- CERT $394,498,000.00
- Revenue This Year
- TAC N/A
- CERT $11.47
- Revenue Next Year
- TAC N/A
- CERT $9.03
- P/E Ratio
- TAC $4,153.91
- CERT N/A
- Revenue Growth
- TAC N/A
- CERT 9.37
- 52 Week Low
- TAC $6.78
- CERT $8.64
- 52 Week High
- TAC $14.64
- CERT $17.76
- Technical
- Relative Strength Index (RSI)
- TAC 63.93
- CERT 41.96
- Support Level
- TAC $8.73
- CERT $11.17
- Resistance Level
- TAC $9.20
- CERT $11.75
- Average True Range (ATR)
- TAC 0.26
- CERT 0.42
- MACD
- TAC 0.10
- CERT -0.06
- Stochastic Oscillator
- TAC 91.96
- CERT 24.00
About TAC TransAlta Corporation
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse and growing fleet of electrical power generation assets in Canada, the United States, and Australia. The company has six reportable segments namely, Hydro, Wind & Solar, Energy Marketing, Gas, Energy Transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.